Full-Time

Director – Enterprise Applications

ERP & Finance Systems

Posted on 9/25/2025

Tarsus Pharamceuticals

Tarsus Pharamceuticals

201-500 employees

Biopharma developing eye-care therapies

Compensation Overview

$203.2k - $284.6k/yr

+ Bonus + Equity

Irvine, CA, USA

Hybrid

Hybrid work environment; remote possible for exceptional candidates with travel to Irvine as needed.

Category
IT & Security (1)
Required Skills
NetSuite
Agile
Inventory Management
Requirements
  • Bachelor’s degree in computer science, Information Systems, Business, Finance or related field with 15+ years of relevant experience in architecting and implementing ERP and other finance, procurement and related systems
  • Strong working knowledge of System Development Life Cycle and Agile methodologies
  • Excellent interpersonal, oral, and written communications skills with the ability to effectively interact with business stakeholders and associates at all levels of management and to effectively communicate technical information to non-technical stakeholders and build strong relationships with cross functional business stakeholders
  • Strong understanding or finance, accounting and procurement business processes and systems and interlinkages to other areas
  • Experience in application integration methodologies for seamless end to end integration and automation
  • Ability to lead and deliver projects and programs across people, process and technology aspects
  • Strong understanding of ERP concepts and business processes, with specific expertise in NetSuite modules such as Financials, Procurement, Inventory Management, and manufacturing
  • Hands-on experience with NetSuite ERP administration in a SOX regulated organization, good experience working with internal and external auditors on SOX audits and IT General controls related to NetSuite
  • A user and service focused mindset to be able to serve the needs of stakeholders and end users with urgency and excellence
  • Excellent vendor management skills. Proven experience with managing external global third-party Managed Services Providers and software vendors
  • Experience in Financial Planning solutions such as Adaptive will be a plus
  • Ability to work independently and collaboratively in a fast paced and dynamic environment
  • People management experience to hire, lead and manage a team of IT business systems analysts and managers
Responsibilities
  • Serve as a trusted strategic partner to finance, accounting and procurement teams and all related areas to identify, advise, recommend and implement technology solutions to enable new business capabilities
  • Lead and implement new system capabilities to scale and automate finance, accounting and procurement functions
  • Lead and manage the IT roadmap for finance, accounting and procurement functions and manage and monitor IT budgets for these business functions
  • Identify, assess and onboard new vendors for specialized projects or support needs
  • Develop, manage and enhance system management processes and controls to ensure efficient operations and compliance with SOX and any other applicable regulations
  • Work cross-functionally across functions including legal, compliance and HR to ensure all business stakeholders are aligned with any new systems capabilities and any impacts or considerations from their perspective
  • Act as a system administrator for NetSuite to manage role-based user access, provide system support and design and implement new capabilities utilizing NetSuite native functionalities, custom workflows and partner systems
  • Review and understand current business processes and bring best practices, and guide finance stakeholders on leveraging NetSuite functionalities to streamline business processes and improve operational efficiency
  • Manage external consultants and managed services vendors for specific projects or ongoing support
  • Provide responsive system support to end users for timely resolution of all issues both directly and through effective management of vendor partners
  • Provide training and support to end users across departments and ensure strong organizational change management for all new projects and capabilities
  • Create and maintain clear documentation of system configurations, processes and customizations
  • Ensure compliance with internal control, data privacy standards and industry regulations
  • As a people leader, hire, train and mentor new team members to support finance, accounting and procurement systems.
Tarsus Pharamceuticals

Tarsus Pharamceuticals

View

Tarsus Pharmaceuticals develops treatments for eye care and infectious diseases. Its FDA-approved product, XDEMVY (lotilaner ophthalmic solution 0.25%), treats Demodex Blepharitis by killing Demodex mites on the eyelids. The company also has a pipeline targeting conditions like Lyme Disease Prevention, Meibomian Gland Disease, and Rosacea, and it earns revenue from selling approved products and collaborating with partners. Its goal is to address unmet medical needs by developing, commercializing, and expanding collaborations to reach more patients.

Company Size

201-500

Company Stage

IPO

Headquarters

Irvine, California

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • XDEMVY nets $145 million Q1 2026 sales, up 85% year-over-year.
  • 2026 guidance projects $670-$700 million XDEMVY sales, 50% growth.
  • $200 million Pharmakon financing supports sales force expansion without dilution.

What critics are saying

  • ICRx Cliradex wipes erode XDEMVY sales by 15-20% within 6-12 months.
  • TP-05 CALLIOPE trial fails efficacy, halts Phase 3 in 12-18 months.
  • Aldeyra reproxalap captures 25% Demodex market share post-2027 approval.

What makes Tarsus Pharamceuticals unique

  • XDEMVY is the only FDA-approved treatment for Demodex blepharitis.
  • TP-05 advances as first-in-class oral Lyme disease preventive in Phase 2 CALLIOPE trial.
  • TP-04 targets untreated ocular rosacea market in Phase 2 with H1 2027 data.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Vacation

Hybrid Work Options

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

0%

2 year growth

2%
Yahoo Finance
Apr 3rd, 2026
Tarsus Pharmaceuticals doses first patient in Phase 2 Lyme disease prevention trial with TP-05

Tarsus Pharmaceuticals has dosed the first participant in its Phase 2 Calliope trial of TP-05, an investigational oral therapy aimed at preventing Lyme disease in approximately 700 at-risk adults across endemic US regions. The programme targets a significant unmet need as a potential first-in-class, non-vaccine prophylactic for Lyme disease, where no FDA-approved preventive drugs currently exist. Whilst the trial marks progress, near-term investment focus remains on XDEMVY adoption and margins. The company recently received a $15 million milestone payment tied to TP-03 approval in China, highlighting monetisation of its lotilaner platform beyond the US. Analyst projections for Tarsus vary widely, with some forecasting $847 million revenue and $237 million earnings by 2028, whilst more cautious estimates suggest $988 million revenue and $188 million earnings by 2029.

Yahoo Finance
Mar 24th, 2026
Tarsus Pharma CHRO sells $839K in shares via mandatory RSU vesting amid 20% stock surge

Dianne Whitfield, Chief Human Resources Officer at Tarsus Pharmaceuticals, sold 12,274 shares of common stock worth approximately $839,000 between 17 and 19 March 2026. The sale represented 25.95% of her direct holdings, reducing her position from 47,302 to 35,028 shares. The transaction was a mandatory "sell to cover" arrangement tied to RSU vesting for tax withholding purposes, rather than a discretionary sale. Shares sold at a weighted average price of $68.36. Tarsus Pharmaceuticals generated $451.4 million in net product sales in 2025, more than doubling from the prior year, driven by adoption of its lead product XDEMVY. The company narrowed its net loss to $66.4 million and ended 2025 with over $417 million in cash and marketable securities.

Yahoo Finance
Feb 24th, 2026
Tarsus Pharmaceuticals projects $670M–$700M 2026 sales as XDEMVY hits profitability

Tarsus Pharmaceuticals reported $450 million in full-year net sales for 2025, with its XDEMVY treatment achieving product-line profitability. The company has expanded its addressable market from nine million to 25 million Americans with Demodex blepharitis as screening becomes routine amongst eye care professionals. The firm projected 2026 net product sales between $670 million and $700 million, representing approximately 50% annual growth at the midpoint. Direct-to-consumer awareness reached 25% amongst surveyed patients, significantly increasing treatment requests. Tarsus plans to expand its sales force by 15 to 20 key account leaders and will initiate a Phase II trial for TP-05 in Lyme disease prevention in Q2 2026. The company has also launched the first Phase II trial for TP-04 in Ocular Rosacea, a category with no currently approved FDA treatments.

GlobeNewswire
Mar 13th, 2025
Tarsus Announces Pricing of Upsized $125.0 Million Public Offering

IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the pricing of...

MarketBeat
Nov 22nd, 2024
Mutual of America Capital Management LLC Invests $4.29 Million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Mutual of America Capital Management LLC invests $4.29 million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS).

INACTIVE